dBET6 is primarily utilized in the field of biomedical research, particularly in the study of protein degradation and targeted therapy. It functions as a proteolysis-targeting chimera (PROTAC), a novel approach designed to selectively degrade specific proteins within cells. This compound is especially significant in cancer research, where it is used to target and degrade proteins that are crucial for the survival and proliferation of cancer cells. By leveraging the ubiquitin-proteasome system, dBET6 facilitates the breakdown of these target proteins, thereby inhibiting cancer cell growth and potentially leading to new therapeutic strategies. Its application extends to the study of various diseases where protein dysregulation plays a critical role, offering a promising avenue for the development of targeted treatments.